XiaoMi-AI文件搜索系统
World File Search SystemDAVA
20-F - Endava plc (DAVA)
全球范围。尽管全球疫苗接种工作正在进行中，包括我们总部所在的英国在内的某些司法管辖区已重新开放企业和政府机构，但企业的实体运营仍然存在限制，全球金融市场也存在不确定性。COVID-19 疫情对全球宏观经济的这种影响可能会降低我们获取资本的能力，因此可能对我们未来的流动性产生负面影响。此外，COVID-19 疫情蔓延导致的持续全球经济不确定性可能会对我们的业务产生重大影响，包括对我们服务的需求以及我们的 ADS 价值。这种财务不确定性还可能对我们服务的定价产生负面影响，或导致我们的客户大幅减少或推迟其技术支出，这反过来可能会降低对我们服务的需求，并对我们的收入、盈利能力和现金流产生负面影响。全球市场的不确定性增加和混乱也可能对我们的增长机会产生负面影响，无论是有机增长还是通过收购实现的增长。
div> dava Striker™návodk obsluze
Testing of the current location as a route point ................................................... 16 Creating a route point in a different position .............................................. 16 Edit of the stored route point ...... 16 Positions .................... 16 Navigation to the route point ................................. 17 Removing route point or mob .........................................积分....... 17分享路线点和不同设备上的路线......................................................................................................................................................................................................................................................................................................................................................................................................... 17
免疫检查点抑制剂对伴随慢性淋巴细胞性白血病患者治疗晚期黑色素瘤的疗效
*通信：德克萨斯大学医学博士Anderson癌症中心手术系Jennifer A. Wargo博士，美国德克萨斯州休斯敦77030，FCT17.6060 1400，美国德克萨斯州。jwargo@mdanderson.org（J.A. Wargo）。披露下巴是美国专利申请的发明者（PCT/US17/53.717）；报告了IMEDEX，DAVA肿瘤学，Omniprex，Illumina，Gilead，Peerveie，Peerveie，Medimmune和Bristol-Myers Speibb（BMS）（BMS）的IMEDEX，DAVA肿瘤学，Omniprex，Illumina，Gilead，gilead，gilead，gilead，gilead，gilead，imniprex和Honoraria的报告；是Roche/Genentech，Novartis，Astrazeneca，GlaxoSmithkline（GSK），BMS，Merck，Biothera Pharmaceuticals和Micromona的顾问/顾问委员会成员。下颌持有Micromona的股票期权。JLM担任默克公司的顾问和Bristol-Myers Squibb的顾问委员会。GVL是Agenus，Amgen，Array Biopharma，Astrazeneca，Boehringer Ingelheim，Bristol-Myers Squibb，Evaxion，Hexal AG（Sandoz Company），Hexal AG（Sandoz Company），突出显示治疗疗法S.L. Provectus，Qbiotics，Regeneron。LW是诺华，默克·夏普（Merck Sharp）和杜姆（Dohme）以及布里斯托尔（Bristol）的顾问顾问/顾问。所有其他作者都没有宣布利益冲突。
DD 表格 2967，“家庭暴力受害者报告选项声明”
限制性报告的例外 在受害者选择限制性报告的情况下，如果出于以下原因进行披露，则将暂停禁止向以下个人或实体披露受保护的通信： 1. 指定个人，且披露已获得受害者书面授权。 2. 指挥部或执法部门在必要时可向其报告，以防止或减轻对受害者或其他人（包括未成年子女）的健康或安全造成的严重和迫在眉睫的威胁。 3. FAP 人员或 HCP 在必要时向指挥部和/或执法部门报告事件信息，以防止或减轻对受害者或其他人（包括未成年子女）的健康或安全造成的严重和迫在眉睫的威胁。 4. FAP 和任何其他依法授权接收虐待或忽视儿童报告的机构，如果由于受害者的披露，DAVA、FAP 临床提供者或 HCP 有合理理由相信也发生了虐待儿童的情况。但是，披露仅限于与虐待/忽视儿童相关的信息。 5. 当 HCP 需要披露信息以适应残疾退休裁定的职责时，向残疾退休委员会和官员披露。披露仅限于处理残疾退休裁定所必需的信息。6. 当需要披露信息以监督直接受害者的治疗或服务时，向 DAVA、FAP 临床提供者或 HCP 的主管披露。7. 当军事、联邦或州法官发出传票要求向法院、官员或实体（法官下令披露）提交所涵盖的通信时，向有管辖权的军事或民事法院提交；或当联邦或州法规或适用的美国国际协议要求时，向其他官员或实体提交。8. 限制性报道不适用于虐待或忽视儿童的案件。所有虐待儿童的行为都是可以报告的，当虐待儿童作为家庭虐待事件的一部分发生时，限制性报道可能会受到影响。
病例报告用pembrolizumab治疗的组织细胞肉瘤：病例报告和文献综述
地址为Daniel Huff（Huff.daniel@mayo.edu）的通信。支持来源：无。Conflict of Interest: Javier Munoz reports the following: consulting for Pharmacyclics/Abbvie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, Beigene，Servier，Novartis，Morphosys/Incyte，Mei Pharma和Zodiac；拜耳，吉利德/风筝制药，塞尔金，默克，波尔托拉，incyte，incyte，genentech，Pharmacyclics，Seattle Genetics，Janssen和Millennium获得的研究资金；有针对性肿瘤学，Oncview，Curio，Kyowa，医师教育资源，DAVA，全球临床见解，MJH和西雅图遗传学的Honoraria；发言人的吉利德/风筝制药局，京止，拜耳，药学/詹森，西雅图遗传学，acrotech/aurobindo，beigine，beigene，verastem，verastem，astrazeneca，celgene/celgene/bms和genentech/genentech/roche/roche。其余作者没有披露。
仿制药 MDL - SCT - 申请复审
以下的请愿人、被告-请愿人是 Actavis Holdco US, Inc.；Actavis Pharma, Inc.；Akorn, Inc.；Akorn Sales Inc.；Amneal Pharmaceuticals, Inc.；Apotex Corporation；Ascend Laboratories, LLC；Aurobindo Pharma USA, Inc.；Citron Pharma, LLC；DAVA Pharmaceuticals, LLC；Dr. Reddy's Laboratories, Inc.；Epic Pharma, LLC；Fougera Pharmaceuticals Inc.；G&W Laboratories, Inc.；Generics Bidco I, LLC；Hi- Tech Pharmacal Co., Inc.；Impax Laboratories, Inc.；Lannett Company, Inc.；Mayne Pharma Inc.；Morton Grove Pharmaceuticals, Inc.；Mylan Inc.；Mylan NV；Mylan Pharmaceuticals Inc.；Oceanside Pharmaceuticals, Inc.；Par Pharmaceutical Companies, Inc.；Par Pharmaceutical, Inc.； Perrigo New York, Inc.；Sandoz Inc.；Sun Pharmaceuticals Industries, Inc.；Taro Pharmaceuticals USA, Inc.；Teva Pharmaceuticals USA, Inc.；UDL Laboratories, Inc.；Upsher-Smith Laboratories, LLC；Valeant Pharmaceuticals International；Valeant Pharmaceuticals North America, LLC；Wockhardt USA LLC；Zydus Pharmaceuticals (USA) Inc.
Cyclin E1/CDK2激活是妇科癌症中WEE1激酶抑制的关键弱点
附加声明：存在利益冲突 D. Kim 是 Zentalis Pharmaceuticals 的员工和股东。H. Chung 是 Zentalis Pharmaceuticals 的员工和股东。W. Liu 是 Zentalis Pharmaceuticals 的员工和股东。S. Kim 是 Zentalis Pharmaceuticals 的员工和股东。X. Guo 是 Zentalis Pharmaceuticals 的员工和股东。N. Jameson 是 Zentalis Pharmaceuticals 的员工和股东。P.R.de Jong 是 Zentalis Pharmaceuticals 的前员工。S. Yea 是 Zentalis Pharmaceuticals 的员工和股东。L. Harford 是 Zentalis Pharmaceuticals 的员工和股东。J. Li 是 Zentalis Pharmaceuticals 的前雇员。D. Kim 是 Zentalis Pharmaceuticals 的员工和股东。K. Fischer 是 Zentalis Pharmaceuticals 的员工和股东。A. Samatar 是 Zentalis Pharmaceuticals 的员工，也是 Zentalis Pharmaceuticals 的股东。A. Jubb 是 Zentalis Pharmaceuticals 的员工和股东。K. Bunker 是 Zentalis Pharmaceuticals 的员工，也是 Zentalis Pharmaceuticals 的股东。K. Blackwell 是 Zentalis Pharmaceuticals 的员工和股东。F. Simpkins 是阿斯利康、葛兰素史克和 Zentalis Pharmaceuticals 的科学顾问委员会成员；已获得阿斯利康、Repare Therapeutics、Instill Bio 和 Sierra Oncology 的机构研究资助。F. Meric-Bernstam 是以下公司的顾问。G.B.Mills 是 Amphista、Astex、阿斯利康、BlueDot、Chrysallis Biotechnology、Ellipses Pharma、GSK、ImmunoMET、In¬nity、Ionis、Leapfrog Bio、Lilly、Medacorp、Nanostring、Nuvectis、PDX Pharmaceuticals、Qureator、Roche、Signalchem Lifesciences、Tarveda、Turbine、Zentalis Pharmaceuticals 的科学顾问委员会/顾问；股票/期权/财务：Bluedot、Catena Pharmaceuticals、ImmunoMet、Nuvectis、SignalChem、Tarveda、Turbine；许可技术：Myriad Genetics 的 HRD 检测、Nanostring 的 DSP 专利；赞助研究：阿斯利康。O. Harismendy 是 Zentalis Pharmaceuticals 的员工和股东。J. Ma 是 Zentalis Pharmaceuticals 的员工和股东。M.R.Lackner 是 Zentalis Pharmaceuticals 的员工和股东。其他作者未报告任何披露。AbbVie、Aduro BioTech Inc.、Alkermes、阿斯利康、第一三共株式会社、Calibr（斯克里普斯研究公司旗下的一个部门）、DebioPharm、Ecor1 Capital、eFFECTOR Therapeutics、Exelixis、F. Hoffman-La Roche Ltd.、GT Apeiron、Genentech Inc.、Harbinger Health、IBM Watson、Incyte、In¬nity Pharmaceuticals、Jackson Laboratory、Jazz Pharmaceuticals、Kolon Life Science、LegoChem Bio、Lengo Therapeutics、Loxo Oncology、Menarini Group、OrigiMed、PACT Pharma、Parexel International、P¬zer Inc.、Protai Bio Ltd、Samsung Bioepis、Seattle Genetics Inc.、Tallac Therapeutics、Tyra Biosciences、Xencor、Zymeworks； Black Diamond、Biovica、Eisai、FogPharma、Immunomedics、Inection Biosciences、Karyopharm Therapeutics、Loxo Oncology、Mersana Therapeutics、OnCusp Therapeutics、Puma Biotechnology Inc.、Seattle Genetics、Sano¬、Silverback Therapeutics、Spectrum Pharmaceuticals、Theratechnologies、Zentalis 的咨询委员会；获得 Jazz Pharmaceuticals、Zymeworks、Aileron Therapeutics, Inc. AstraZeneca、Bayer Healthcare Pharmaceutical、Calithera Biosciences Inc.、Curis Inc.、CytomX Therapeutics Inc.、Daiichi Sankyo Co. Ltd.、Debiopharm International、eFFECTOR Therapeutics、Genentech Inc.、Guardant Health Inc.、Klus Pharma、Takeda Pharmaceutical、Novartis、Puma Biotechnology Inc.、Taiho Pharmaceutical Co. 的赞助研究（对机构而言）；Dava Oncology 的酬金；获得欧洲癌症研究与治疗组织 (EORTC)、欧洲肿瘤医学学会 (ESMO)、胆管癌基金会、Dava Oncology 的旅行相关资金和报销。
Creelan-IOV-COM-202-Cohort-3A- ...
参考文献 1. Zhou S 等人。Front Immunol。2023；14：1129465。2. Schoenfeld AJ 等人。Cancer Discov。2024；14：1389–402。3. Garon B 等人。N Engl J Med。2015；37：2018–28。缩写 AE，不良事件；BOR，最佳总体缓解；CI，置信区间；CR，完全缓解；CY，环磷酰胺；DCR，疾病控制率；DOR，缓解持续时间；ECOG，东部肿瘤协作组；EGFR，内皮生长因子受体；EOA，评估结束；EOS，研究结束；EOT，治疗结束；FLU，氟达拉滨；GMP，良好生产规范；ICI，免疫检查点抑制剂；IL-2，白细胞介素-2；NE，不可评估； NR，未达到；NSCLC，非小细胞肺癌；ORR，客观缓解率；PD，进展性疾病；PD-L1，程序性细胞死亡-1配体；PR，部分缓解；PS，体能状态；Q3W，每 3 周一次；Q6W，每 6 周一次；RECIST，实体肿瘤疗效评价标准；SD，疾病稳定；SOD，直径总和；TEAE，治疗中出现的不良事件；TIL，肿瘤浸润淋巴细胞；TKI，酪氨酸激酶抑制剂；TPS，肿瘤比例评分；wt，野生型。披露 Benjamin C Creelan：Achilles Therapeutics plc、Aptitude Health、AstraZeneca、Boehringer-Ingelheim、DAVA Oncology、ER Squibb & Sons, LLC、G1 Therapeutics, Inc、Hoffman LaRoche、Iovance Biotherapeutics、Jannsen、Johnson&Johnson、MJH Healthcare Holdings, LLC、OmniHealth Media、Regeneron、VJ HemeOnc；Kai He：AbbVie、Adaptimmune、Amgen、AstraZeneca、BioNTech SE、Bristol Myers Squibb、Genentech/Roche、GSK、Iovance Biotherapeutics、Lyell Immunopharma、Mirati Therapeutics、Obsidian Therapeutics、OncoC4、Perthera； Edward Garon：A2 Bio、AbbVie、ABL-Bio、Arcus、Arrivent、AstraZeneca、Atreca、Black Diamond Therapeutics、BridgeBio、Bristol Myers Squibb、Daiichi-Sankyo、Eli Lilly、EMD Serono、Genentech、Gilead、Hookipa、I-Mab、Iovance Biotherapeutics、iTeos、LianBio、Merck、Merus、Mirati、Novartis、Nuvalent、Pfizer、Prelude、Regeneron、Sanofi、Seagan、Sensei、Sumitomo、Strata、Summit、Synthekine、TILT Biotherapeutics；Jason Chesney：无可披露；Sylvia Lee：Bristol Myers Squibb、Iovance Biotherapeutics、Kite Pharma、Lyell Immunopharma、Seagen； Jorge Nieva：Aadi Biosciences、Affyimmune、ANP Technologies、AstraZeneca、BioAtla、Cansera、Epic Sciences、G1 Therapeutics、Genentech、Indee Bio、Kalivir、Merck、MindMed、Naveris、Sanofi；Adrian Sacher：AdaptImmune、Amgen、AstraZeneca、BridgeBio、Bristol Myers Squibb、CRISPR Therapeutics、Genentech、Genentech-Roche、GSK、HotSpot Therapeutics、Iovance Biotherapeutics、Lilly、Merck、Pfizer、Spectrum；Friedrich Graf Finckenstein：专利、版权费、其他知识产权：Bristol Myers Squibb；就业情况：Iovance Biotherapeutics。股票或股票期权：Iovance Biotherapeutics； Brian Gastman、Jeffrey Chou、Rana Fiaz、Melissa Catlett、Guan Chen：Iovance Biotherapeutics；Adam Schoenfeld：Achilles Therapeutics、Affini-T Therapeutics、安进、阿斯利康、百时美施贵宝、cTRL therapy、Enara Bio、GSK、Harpoon Therapeutics、Heat Biologics、Immunocore、Iovance Biotherapeutics、Johnson&Johnson、KSQ Therapeutics、Legend Biotech、Legend Therapeutics、Lyell Immunopharma、Merck、Obsidian Therapeutics、Oppenheimer and Co、PACT Pharma、Perceptive Advisors、Prelude Therapeutics、Regeneron、Synthekine、Umoja Biopharma。致谢 • 本研究由 Iovance Biotherapeutics, Inc.（美国加利福尼亚州圣卡洛斯）赞助 • 医学写作和编辑支持由 OPEN Health 公司 Peloton Advantage, LLC 提供，并由 Iovance 资助 • 特别感谢 IOV-COM-202 研究患者及其家属
2023行政年度报告伊斯坦布尔
表88。 Öğrenci Kontenjanları ve Doluluk Oranı ................................................................ 101 Tablo 89. İkametgahın Kayıtlı Olduğu İl Bazında Öğrenci Sayıları ......................................... 101 Tablo 90. 2023 MÜYÖS Bilgileri ............................................................................................. 102 Tablo 91. 2023穆耶斯的学生人数........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... Hizmet Birimlerinin Hasta ve Tetkik Bilgileri .......................................................... 104 Tablo 93. Nöroloji Birimleri Hizmet Bilgileri .......................................................................... 104 Tablo 94. Anabilim Dalı Bazında Hasta Sayıları ...................................................................... 105 Tablo 95. 根据部门（TL）106 106表96的总交易金额。 Radyolojik Tetkik Adedi .......................................................................................... 107 Tablo 97. Mediko-Sosyal Hizmet Bilgileri ............................................................................... 108 Tablo 98. yemek hizmeti verenyerleşkeler......................................................................................................................................................................................................................................................... 2023 Yılı Yemek Ücretleri ....................................................................................... 109 Tablo 100. 2023 Yılı Yemek Hizmetinden Yararlanan Kişi Sayısı ............................................ 109 Tablo 101.表88。Öğrenci Kontenjanları ve Doluluk Oranı ................................................................ 101 Tablo 89.İkametgahın Kayıtlı Olduğu İl Bazında Öğrenci Sayıları ......................................... 101 Tablo 90.2023 MÜYÖS Bilgileri ............................................................................................. 102 Tablo 91.2023穆耶斯的学生人数........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... .......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................Hizmet Birimlerinin Hasta ve Tetkik Bilgileri .......................................................... 104 Tablo 93.Nöroloji Birimleri Hizmet Bilgileri .......................................................................... 104 Tablo 94.Anabilim Dalı Bazında Hasta Sayıları ...................................................................... 105 Tablo 95.根据部门（TL）106 106表96的总交易金额。Radyolojik Tetkik Adedi .......................................................................................... 107 Tablo 97.Mediko-Sosyal Hizmet Bilgileri ............................................................................... 108 Tablo 98.yemek hizmeti verenyerleşkeler.........................................................................................................................................................................................................................................................2023 Yılı Yemek Ücretleri ....................................................................................... 109 Tablo 100.2023 Yılı Yemek Hizmetinden Yararlanan Kişi Sayısı ............................................ 109 Tablo 101.Kültürel Kurslar .................................................................................................... 111 Tablo 102.faaliyetTürlerivesayıları.................................................................................................................................................................................................................................Şehir İçi ve Şehirler Arası Görev Sayıları .............................................................. 114 Tablo 104.2023 Yılı Öğrenci Ring Seferleri ............................................................................. 115 Tablo 105.Üniversite Araç Bilgileri ........................................................................................ 115 Tablo 106.İş Makinası Bilgileri ............................................................................................... 116 Tablo 107.Kiralık Araç Bilgileri ............................................................................................... 116 Tablo 108.Kulüp İsimleri........................................................................................................ 116 Tablo 109.bilimsel projesayılarıBilgileri.................................................................................................................................................................................................................................................................按菲尔德人对科学研究项目的分配和预算。122表111。Birimlere Göre Proje Sayıları ve Bütçeleri ............................................................ 124 Tablo 112.BAPKO Bütçesinden Yapılan Harcamalar ............................................................. 125 Tablo 113.Birimlere Göre TÜBİTAK Proje Bilgileri ................................................................ 126 Tablo 114.diğerProjeler ve bilgileri .................................................................................................................................................................................................................................................................................................................2023YılındaYapılanPateNtBaşvuruları.........................................................................................................................................................................................................................................................................................................................................2023年的专利注册2023年制作的有用模型应用Bilimsel Hakemliklerin Yıllara Göre Dağılımı ........................................................ 131 Tablo 119.2023 Yılında Tamamlanan Bilimsel Araştırma Projelerinden Üretilen Yayın Tablosu ................................................................................................................................... 131 Tablo 120.Akademik Teşvik Alan Öğretim Elemanı Dağılımı ................................................ 131 Tablo 121.Kurumsal İletişim Koordinatörlüğü Faaliyet Verileri ............................................ 132 Tablo 122.Marmara Üniversitesi Sosyal Medya Durum Analizi ............................................ 133 Tablo 123.Kariyer Merkezi Faaliyetleri .................................................................................. 133 Tablo 124.Bursa Alan Öğrenci Sayısı .................................................................................................................................................................................................................................................................................................................................................ERASMUS Gelen-Giden Öğrenci Sayıları .............................................................. 138 Tablo 126.伊拉斯mus人数............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ...................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................MarmaraüniversItesiuluslararasıAnlaşmalarve te原子器.................................................................................................................................................................................................................................................................................................................................................................................................Farabi Değişim Programı İkili Anlaşmalar ............................................................ 153 Tablo 129.eğitim-ÖğretimDönemlerineGörefarabiöğrenciSayıları.......................................................................................................................................................................................................................................................Mahkeme Dava Bilgileri ....................................................................................... 156 Tablo 131.Numerical data on the cases where our university is dealing with ......................... 157 Table 132. 在2023年开放并转移了...Numerical data on the cases where our university is dealing with ......................... 157 Table 132.在2023年开放并转移了...